Feedback plc (LSE:FDBK), developer of the Bleepa platform, remains in a holding pattern as it waits for a central NHS decision that could transform its prospects. The group said in July that it ended its financial year to 31 May 2026 with about £2.7m of cash, ahead of its own expectations, and that its funds should last until mid-2027. A potential national contract for Bleepa, however, has yet to be decided, and the timing remains outside the company's control.

What the company does

Feedback develops Bleepa, a clinical communications and medical imaging platform designed to help NHS clinicians share information and manage patient pathways outside traditional outpatient settings. Bleepa accounted for roughly 89% of sales in a recent reporting period. The company's strategy centres on community diagnostic pathways, where the platform is used to triage and manage patients referred by GPs.

Latest developments

In an April update, Feedback said a central NHS decision on a possible widescale Bleepa adoption contract, previously expected around 31 March 2026, had slipped by at least six to nine months because of factors internal to the NHS. NHS England extended Bleepa licences at Queen Victoria Hospital, with an annualised contract value of £495,000, to cover the nine months to December 2026. A further annual extension was agreed with Northern Care Alliance NHS Foundation Trust, while the company chose not to renew a lower-value photocapture contract with Royal Berkshire NHS Foundation Trust.

The July trading update added that integration with the NHS e-Referral Service had produced a tenfold increase in GP practices referring into Bleepa within weeks. Bleepa version 1.7 was released, an insomnia pathway built with Patients Know Best has been rolled out across Kent, Surrey and Sussex, and NHS England has encouraged the company to expand its Sussex deployment to strengthen the evidence base. Management said it hoped for a national decision around the end of the calendar year.

Financial and dividend picture

Revenue for the year to May 2026 was about £0.8m, broadly flat against £0.9m a year earlier, according to the unaudited trading update. The EBITDA loss was smaller than both expectations and the prior year, reflecting cost controls. In the previous year to May 2025, Feedback reported revenue of £885,623, an EBITDA loss of £3.06m and a post-tax loss of £7.32m, including a £3.19m intangible impairment. The company does not pay a dividend, as it continues to invest in growth while loss-making.

Sector and index context

Feedback (LSE:FDBK) is one of the smaller health technology names in the FTSE AIM All Share Index, a benchmark that tracks a wide spread of growth and early-stage companies. As of 21 August 2026, the shares stood at 6.85p after an 11% one-day rise on no fresh news, giving a market value of about £3m. The stock had more than halved over the previous year, and trading volumes are often thin, which can amplify price swings.

Key risks

The most significant risk is dependence on slow and unpredictable NHS procurement, with the central decision already delayed once. Revenue has historically been concentrated, with one customer providing about 55% of turnover in the year to May 2025. Continued cash burn means a further fundraising could be needed before profitability, potentially at a depressed share price, and NHS reorganisation could disrupt commissioning plans.

What to watch next

Investors will look for news of the NHS national adoption decision, which management hoped would come around the end of 2026, along with any link to 2026/27 frontline digitisation funding. Audited full-year results, renewal of the Queen Victoria Hospital licences beyond December 2026, new pathway deployments and commissioning interest from integrated care boards are other milestones to monitor.